BioCentury
ARTICLE | Clinical News

NT-13: Started Phase I

August 5, 2002 7:00 AM UTC

Nyxis Neurotherapies Inc., Chicago, Ill. Product: NT-13 Business: Neurological Therapeutic category: Receptor agonist Target: NMDA receptor Description: NMDA receptor modulator Indication: Treat neu...